← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Synthis Therapeutics, Inc.
New York City, NY
$3,109,651
Total funding
4
Grants
Funding over time
peak $1.4M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,109,651 · 4
By mechanism
R44$1,999,830 · 1
R43$1,109,821 · 3
Investigators at Synthis Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients$1,420,853
R44 · FY2025 · CA
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients$578,977
R44 · FY2024 · CA
Development of a T cell-targeted TGF-b antagonist that reverses immune suppression in melanoma patients$299,946
R43 · FY2018 · CA
Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients$299,900
R43 · FY2023 · HL
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients$243,905
R43 · FY2019 · CA
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients$210,000
R43 · FY2020 · CA
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients$56,070
R43 · FY2019 · CA